Figure 3. Cumulative incidence of relapse or progressive disease
Cumulative incidence of relapse or progressive disease (PD) since the initiation of IREC therapy: (A) for all patients; (B) according to the disease status at the beginning of first IREC therapy; (C) according to the UGT1A1 genotype.
IREC, irinotecan, etoposide, and carboplatin.